Sandoz management has received reports that some employees of the local company TCA, based nearby, have been feeling unwell. The company identified the problem and quickly fixed it, notifying APPA.
The Sandoz Industrial Products SpA plant informs that today, at 4 in the morning, a modest biological sludge spill occurred during maintenance operations on the purifier.
The problem was identified and quickly fixed.
The company immediately notified the environmental protection agency about the event.
Sandoz management has received reports that some employees of the local company TCA, based nearby, have been feeling unwell.
The management of Sandoz immediately contacted the owner of the TCA company to ascertain the situation, who confirmed the information and specified that the six employees of the company had gone to the local emergency room as a precaution for a check-up, following of which they were all discharged, as confirmed by the management of the TCA itself.
The Sandoz Industrial Products SpA company is in continuous contact with both the TCA company and the competent local authorities to provide full cooperation and to monitor the progress of the matter.
Finally, it should be noted that the periodic maintenance of the water purification plant has been previously and regularly communicated to the competent authorities of the Municipality and of the Province.
Sandoz
Sandoz, a Novartis Group company, is a global leader in the manufacture and marketing of generic medicines.
Present in over 160 countries and with over 26,500 employees worldwide, Sandoz offers a broad portfolio of quality generic medicines at an affordable price.
With global revenues of $9.2 billion in 2013, Sandoz has a product portfolio of approximately 1100 molecules and holds worldwide leadership in the Biosimilars sector, as well as in the off-patent areas of injections-oncology, ophthalmology, dermatology and of antibiotics.
Sandoz products are present in the main therapeutic areas and include medicines for the cardiovascular system, treatments for the central nervous system and in the area of chronic pain, medicines for disorders of the gastrointestinal tract and metabolism, cancer and respiratory therapies and treatments for blood and hematopoietic organs.
Sandoz develops, manufactures and markets these medicines as well as active pharmaceutical and biotechnological ingredients and distinguishes itself through its ability to develop and produce complex value-added products, which represent almost half of the Sandoz portfolio.
In addition to strong organic growth in recent years, Sandoz has made a number of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (USA), EBEWE Pharma (Austria), Oriel Therapeutics (USA) , Falcon (USA) and Fougera (USA).
